Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 15/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.38 |
| ▸ | HPD | P32754 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23357599 | 1.00 | BCL6 (0.42) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL20569695 | 0.82 | BCL6 (0.55) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL20568808 | 0.81 | CYP1A2 (0.47) | BCL6ALDH1A1MAPTTP53SMN1; SMN2 | |
| SCHEMBL20569754 | 0.79 | KDM4E (0.48) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL31520616 | 0.77 | BCL6 (0.49) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL20568935 | 0.76 | KDM4E (0.45) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL31520723 | 0.75 | BCL6 (0.48) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL31520583 | 0.74 | ALDH1A1 (0.46) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL31520609 | 0.74 | KDM4E (0.43) | BCL6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL20569856 | 0.73 | KDM4E (0.58) | BCL6KDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | BCL6 1/4885KDM4E 309/4885ALDH1A1 1654/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | BCL6 1/4885KDM4E 309/4885ALDH1A1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.